Comparative Pharmacology
Head-to-head clinical analysis: LIPOFEN versus TRIGLIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIPOFEN versus TRIGLIDE.
LIPOFEN vs TRIGLIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lipofen (fenofibrate) is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It activates PPARα, which increases lipolysis and elimination of triglyceride-rich particles from plasma by stimulating lipoprotein lipase activity and reducing apolipoprotein C-III production. This leads to decreased triglyceride levels and increased HDL cholesterol.
TRIGLIDE (fenofibrate) is a peroxisome proliferator-activated receptor alpha (PPARα) activator. It increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apolipoprotein C-III.
For hypertriglyceridemia: 67-134 mg (as fenofibric acid) orally three times daily with meals. Maximum dose 200 mg/day.
Initial dose: 60 mg (1 tablet) twice daily, gradually increased over 3-7 days to maintenance dose of 120 mg twice daily.
None Documented
None Documented
5-7 hours (prolonged in renal impairment; may exceed 24 hours in severe CKD).
22-35 hours; prolonged in renal impairment (up to 50 hours).
Primarily renal (90% as unchanged drug), with <5% fecal.
Primarily renal (70% as unchanged drug), 20% fecal, <10% biliary.
Category C
Category C
Fibrate Antilipemic
Fibrate Antilipemic